GPO & IDN Strategy
There Is No “Off Season” in GPO Contracting
Contract management does not begin when an RFP is released and end when an award is announced. For medical device companies, the GPO contracting cycle runs continuously — and the companies that treat it that way consistently outperform those that only respond when the paperwork arrives.
For many medical device companies, securing a Group Purchasing Organization (GPO) contract is treated as a milestone — a discrete event to prepare for, win, and then move past. One of the most common and most costly misconceptions among emerging healthcare companies is the belief that contract management begins when an RFP is released and ends when an award is announced.
In reality, there is no downtime in the GPO contracting cycle. The process is continuous — planning, intelligence gathering, relationship building, and strategic positioning all happen long before a formal Request for Information (RFI) or Request for Proposal (RFP) ever reaches the market.
A Cycle That Never Fully Stops
Many GPOs begin evaluating categories and supplier landscapes as much as eighteen months before a contract's expiration, typically through an RFI. A formal RFP often follows roughly twelve months prior to the eventual award. Even after a contract is awarded, the cycle does not end — it continues through contract extensions, category expansions, technology additions, and mid-cycle amendments that regularly create new openings for suppliers willing to stay engaged.
For established manufacturers with dedicated national accounts and contracting teams, monitoring this activity is a full-time responsibility, built into the organization's operating rhythm. For startups and smaller medical device companies, keeping track of multiple GPOs, overlapping contract timelines, shifting stakeholders, and evolving category strategy can become genuinely overwhelming — particularly without a team dedicated to watching it.
The GPO contracting cycle doesn't pause between awards. It simply moves to a phase most companies aren't watching.
The Real Challenge Isn't the RFP
Responding to a released RFP is the easy part. The harder, more consequential challenge is understanding what is happening well before that document exists.
- Which contracts are approaching expiration
- When RFIs are likely to be issued
- What market intelligence is shaping GPO category strategy
- Which health systems are driving demand for a given category of innovation
- How to position a solution before the formal contracting process even begins
- Where opportunities for mid-cycle additions or technology evaluations may already exist
Success in the GPO market is rarely determined by the quality of the proposal alone. It is determined by how much preparation happened long before the procurement documents were ever released.
How Healthcare Solutions US Helps Companies Stay Ahead of the Cycle
At Healthcare Solutions US, we help medical device companies navigate this complexity every day. With direct experience in health system sales, GPO contracting, and market access strategy, our team understands how healthcare purchasing decisions are actually made — and how manufacturers can position themselves well ahead of the opportunities that matter.
We work with organizations on contract-cycle planning, RFI and RFP strategy, stakeholder mapping, market intelligence, contract launch preparation, and ongoing monitoring of a GPO landscape that rarely stays still for long.
Whether You're First In or Already Established
Whether an organization is an early-stage startup preparing for its first GPO engagement, or an established manufacturer expanding its contracting footprint, the same principle holds: understanding the continuous nature of the contract cycle is not optional. It is the difference between reacting to opportunities and shaping them.
The GPO landscape can be difficult to navigate. It does not have to be navigated alone.
Related insights
Product Launch
Calibration for Success: Why Physician Preference Items Require More Than Physician Preference
Physician advocacy can open the door, but health-system adoption depends on alignment across clinical, operational, supply-chain, and value-analysis stakeholders.
Market Access
Why Market Access — Not Just Innovation — Determines Success in U.S. Healthcare
Clinically superior products still stall in the U.S. market. Here is why market access, not innovation alone, decides which technologies scale.
Reading about the constraint is not the same as removing it.
Give us fifteen minutes and we'll show you how we can help.